angiotensin (1-7) inhibits ang ii-mediated erk1/2 activation by stimulating mkp-1 activation in vascular smooth muscle cells

The renin–angiotensin system (ras) exerts profound physiological effects on blood pressure regulation and fluid homeostasis, mainly by modulating renal, cardiovascular, and central nervous systems. angiotensin (ang)-(1-7), an end-product of ras, is recognized by its cardiovascular protective properties through stimulation of the mas receptor, including vasodilation, anti-inflammatory, and antihypertensive actions, and consequently, counter-regulating the well-known ang ii-elicited actions. the overall hypothesis of this study is that ang-(1-7) inhibits ang ii-induced erk1/2 activation in vascular smooth muscle cells (vsmcs), via regulation of mitogen-activated protein phosphatase-1 (mkp-1) activity. aortas from male wistar rats were incubated with ang-(1-7) or vehicle. concentration-response curves to ang ii were performed in endothelium-denuded aortas, in the presence or absence of erk1/2 (pd98059) inhibitor or mas receptor (a-779) antagonist. expression of proteins was assessed by western blot, and immunohistochemistry was conducted in vsmcs. ang-(1-7) incubation decreased ang ii-induced contractile response in aortas, and this effect was not observed in the presence of pd98059 or a-779. stimulation of vsmcs with ang-(1-7) prevented ang ii-induced erk1/2 phosphorylation, but not c-raf-activation. furthermore, ang ii decreased mkp-1 phosphorylation in vsmcs. interestingly, simultaneous incubation of ang-(1-7) with ang ii favored mkp-1 phosphorylation, negatively modulating erk1/2 activation in vsmcs. the results suggest that ang-(1-7) counter-regulates actions evoked by ang ii overproduction, as observed in cardiovascular diseases, mainly by modulating mkp-1 activity. this evidence suggests that the role of ang-(1-7) in mkp-1-regulation represents a target for new therapeutic development.